Precigen (PGEN) director exercises RSUs, adds 71,839 common shares

Rhea-AI Filing Summary

Precigen, Inc. director Fred Hassan exercised restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full, with each unit converting into one share of Precigen common stock at an exercise price of $0.00 per share.

Following this derivative exercise, Hassan directly owned 1,243,239 shares of Precigen common stock. The filing shows acquisitions only, with no open-market purchases or sales reported in this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hassan Fred

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		71,839	A	(1)	1,243,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		M			71,839	(2)	(2)	Common Stock	71,839	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested in full on March 13, 2026.

	/s/ Fred Hassan, by Donald P. Lehr, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Precigen (PGEN) director Fred Hassan report?

Fred Hassan reported exercising restricted stock units into Precigen common shares. On March 13, 2026, 71,839 RSUs vested and converted into an equal number of common shares at $0.00 per share, increasing his directly held common stock position.

How many Precigen (PGEN) shares does Fred Hassan hold after this Form 4?

After the reported transactions, Fred Hassan directly holds 1,243,239 shares of Precigen common stock. This total reflects the addition of 71,839 shares received from the full vesting and conversion of restricted stock units reported as of March 13, 2026.

Were Fred Hassan’s Precigen (PGEN) transactions open-market buys or sales?

The transactions were not open-market buys or sales. They reflect a derivative exercise, where 71,839 restricted stock units vested and converted into common shares at $0.00 per share, with no reported market purchases or dispositions in this Form 4.

What are the key details of the restricted stock units in the Precigen (PGEN) filing?

Each restricted stock unit represented a contingent right to receive one share of Precigen common stock. All 71,839 RSUs vested in full on March 13, 2026 and were exercised at $0.00 per unit, resulting in issuance of an equal number of common shares.

Does the Precigen (PGEN) Form 4 show any remaining derivative holdings for Fred Hassan?

The Form 4 indicates no remaining derivative position related to this transaction. The derivativeSummary section is empty and the 71,839 restricted stock units reported were fully vested and converted into common stock on March 13, 2026.